T Pincikova1,2,3, D Paquin-Proulx3, J K Sandberg3, M Flodström-Tullberg3, L Hjelte1,2. 1. Stockholm CF Center, Karolinska University Hospital Huddinge, Stockholm, Sweden. 2. Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. 3. Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Abstract
BACKGROUND/ OBJECTIVES: Vitamin D insufficiency in cystic fibrosis is common. Vitamin D3 is currently preferred over D2. We aimed to study the efficacy of vitamin D2 and D3 at increasing serum 25-hydroxyvitamin D (s25OHD) concentrations and their effect on respiratory health in cystic fibrosis. SUBJECTS/ METHODS:Sixteen CF patients were randomized to receive vitamin D2 or D3 or to serve as controls. The starting dose of 5000 IU (<16 years old) or 7143 IU/day (⩾16 years old) was further individually adjusted. Three months of intervention were followed by two of washout (ClinicalTrials.gov NCT01321905). RESULTS: To increase s25OHD, the mean daily dose of vitamin D2 and D3 had to be increased up to 15650 and 8184 IU, respectively. The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P<0.05). Patients provided vitamin D3 improved FVC at the end of the trial (P<0.05). Change in s25OHD was positively correlated with changes in the adult Quality-of-Life respiratory score at the end of supplementation (P=0.006, r=0.90), and with changes in FEV1 (P=0.042, r=0.62) and FVC (P=0.036, r=0.63) at one month of washout. CONCLUSIONS:Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF.
RCT Entities:
BACKGROUND/ OBJECTIVES:Vitamin Dinsufficiency in cystic fibrosis is common. Vitamin D3 is currently preferred over D2. We aimed to study the efficacy of vitamin D2 and D3 at increasing serum 25-hydroxyvitamin D (s25OHD) concentrations and their effect on respiratory health in cystic fibrosis. SUBJECTS/ METHODS: Sixteen CF patients were randomized to receive vitamin D2 or D3 or to serve as controls. The starting dose of 5000 IU (<16 years old) or 7143 IU/day (⩾16 years old) was further individually adjusted. Three months of intervention were followed by two of washout (ClinicalTrials.gov NCT01321905). RESULTS: To increase s25OHD, the mean daily dose of vitamin D2 and D3 had to be increased up to 15650 and 8184 IU, respectively. The combined group of vitamin D2 and D3 treated patients decreased plasma IL-8 (P<0.05). Patients provided vitamin D3 improved FVC at the end of the trial (P<0.05). Change in s25OHD was positively correlated with changes in the adult Quality-of-Life respiratory score at the end of supplementation (P=0.006, r=0.90), and with changes in FEV1 (P=0.042, r=0.62) and FVC (P=0.036, r=0.63) at one month of washout. CONCLUSIONS:Vitamin D supplementation may contribute to reduced inflammation and improved lung function in CF.
Authors: V Tangpricha; A Kelly; A Stephenson; K Maguiness; J Enders; K A Robinson; B C Marshall; D Borowitz Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: Isabelle Sermet-Gaudelus; Maria Luisa Bianchi; Michèle Garabédian; Robert M Aris; Alison Morton; Dana S Hardin; Sarah L Elkin; Juliet E Compston; Steven P Conway; Mireille Castanet; Susan Wolfe; Charles S Haworth Journal: J Cyst Fibros Date: 2011-06 Impact factor: 5.482
Authors: T Pincikova; K Nilsson; I E Moen; F Karpati; G Fluge; A Hollsing; P K Knudsen; A Lindblad; L Mared; T Pressler; L Hjelte Journal: Eur J Clin Nutr Date: 2010-09-22 Impact factor: 4.016
Authors: William P Sexauer; Anas Hadeh; Pamela A Ohman-Strickland; Robert L Zanni; Laurie Varlotta; Douglas Holsclaw; Stanley Fiel; Gavin R Graff; Arthur Atlas; Dorothy Bisberg; Denis Hadjiliadis; Suzanne H Michel; Daria Mintz; Rebanta Chakraborty; Bridget Marra; Paula Lomas; Tara Ward; Meagen Sassman; Giovanna C Imbesi; Diane M Kitch; Allison M Mallowe Journal: J Cyst Fibros Date: 2015-01-07 Impact factor: 5.482
Authors: Vin Tangpricha; Joshua Lukemire; Yuqing Chen; José Nilo G Binongo; Suzanne E Judd; Ellen S Michalski; Moon J Lee; Seth Walker; Thomas R Ziegler; Rabin Tirouvanziam; Susu M Zughaier; Supavit Chesdachai; Wendy A Hermes; James F Chmiel; Ruth E Grossmann; Amit Gaggar; Patricia M Joseph; Jessica A Alvarez Journal: Am J Clin Nutr Date: 2019-03-01 Impact factor: 7.045
Authors: Katharina Staufer; Emina Halilbasic; Peter Hillebrand; Solveig Harm; Stefan Schwarz; Peter Jaksch; Danijel Kivaranovic; Walter Klepetko; Michael Trauner; Lili Kazemi-Shirazi Journal: United European Gastroenterol J Date: 2018-05-17 Impact factor: 4.623
Authors: Jim Bartley; Jeff Garrett; Carlos A Camargo; Robert Scragg; Alain Vandal; Rose Sisk; David Milne; Ray Tai; Gene Jeon; Ray Cursons; Conroy Wong Journal: Chron Respir Dis Date: 2018-02-28 Impact factor: 2.444
Authors: Anirudh Bhimavarapu; Qiao Deng; Marta Bean; Nick Lee; Thomas R Ziegler; Jessica Alvarez; Vin Tangpricha Journal: Am J Med Sci Date: 2020-08-20 Impact factor: 2.378